“We welcome the Prime Minister’s call for global action to tackle the development of new antibiotics. Antibiotics play a crucial role in modern medicine, saving lives, treating infection and supporting many important medical interventions – such as surgery, implants, transplants and chemotherapy.
“The R&D-based pharmaceutical industry continues to invest millions of pounds in the development of new antibiotics and considerable expertise remains in the industry; however, we know that antibiotics are undervalued and their price has not always reflected their value to society. It is widely recognised that we are not seeing enough development of new and novel classes of antibiotics due to scientific, regulatory and financial obstacles. Antimicrobial resistance is a serious global issue, which requires a multi-stakeholder response. Confronted with the high costs and long lead times of developing new medicines, the pharmaceutical industry and governments need to work in partnership as a matter of urgency to create aligned incentives to encourage the development of new antibiotics. We welcome the UK Government’s commitment to the independent review, and the ABPI is looking forward to contributing to it, including exploring alternative economic models that will support appropriate prescribing.”